Assessing the Emergence of Resistance: The Absence of Biological Cost In Vivo May Compromise Fosfomycin Treatments for P. aeruginosa Infections

@inproceedings{RodrguezRojas2010AssessingTE,
  title={Assessing the Emergence of Resistance: The Absence of Biological Cost In Vivo May Compromise Fosfomycin Treatments for P. aeruginosa Infections},
  author={Alexandro Rodr{\'i}guez-Rojas and Mar{\'i}a Dolores Maci{\'a} and Alejandro Couce and Cristina Luna G{\'o}mez and Alfredo Casta{\~n}eda-Garc{\'i}a and Antonio Oliver and Jes{\'u}s Bl{\'a}zquez},
  booktitle={PloS one},
  year={2010}
}
BACKGROUND Fosfomycin is a cell wall inhibitor used efficiently to treat uncomplicated urinary tract and gastrointestinal infections. A very convenient feature of fosfomycin, among others, is that although the expected frequency of resistant mutants is high, the biological cost associated with mutation impedes an effective growth rate, and bacteria cannot offset the obstacles posed by host defenses or compete with sensitive bacteria. Due to the current scarcity of new antibiotics, fosfomycin… CONTINUE READING